HeartBeam (NASDAQ: BEAT) was featured in a recent article discussing its collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology. The publication indicates that the move highlights HeartBeam’s growing focus on artificial intelligence-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.
The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high-value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management.
HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management.
The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit HeartBeam.com. To view the full article about the collaboration, visit https://ibn.fm/oTJHB. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Please see full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
